NRG-GY016

Terminated

Return to Protocol Table

A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary

Principal Investigator

Lilian Gien

Status

Terminated

Open to Accrual

September 28, 2018

Temporarily Closed to Accrual

April 10, 2019

Closed to Accrual

April 10, 2019

Terminated

February 1, 2021

Closed to Accrual

February 1, 2021

Closed to Accrual & Treatment

February 19, 2021

Closed to Accrual & Treatment

February 1, 2021

Terminated

February 1, 2021

Complete

February 1, 2021

Terminated

March 27, 2024


Disease Site

Gynecologic [GY] Ovarian

Phase

II

Developmental Therapeutics

No

Primary Objective

To assess the objective tumor response (proportion of objective response by RECIST 1.1 criteria) of the combination of MK-3475 (pembrolizumab) and epacadostat in patients with recurrent or persistent clear cell carcinoma of the ovary

 

Patient Population

Women with recurrent or persistent clear cell carcinoma of the ovary.

Target Accrual

23

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.


Patient Study Webpage

There is no available patient study webpage available for this trial at this time.